For example, studies have demonstrated that BETi resistance is mediated by adaptive kinome reprogramming in ovarian cancer (OC) [33], neuroblastoma [19], or SPOP-mutated prostate cancer [32]. This evidence concerns the gene SPOP and ovarian cancer.